- Home
- BIAF vs APLM Comparison
BIAF vs APLM Comparison
Compare BIAF & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- APLM
- Stock Information
- Founded
- BIAF 2014
- APLM 2016
- Country
- BIAF United States
- APLM United States
- Employees
- BIAF N/A
- APLM N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- APLM Blank Checks
- Sector
- BIAF Health Care
- APLM Finance
- Exchange
- BIAF Nasdaq
- APLM Nasdaq
- Market Cap
- BIAF 7.1M
- APLM 6.1M
- IPO Year
- BIAF 2022
- APLM N/A
- Fundamental
- Price
- BIAF $0.24
- APLM $5.16
- Analyst Decision
- BIAF Hold
- APLM
- Analyst Count
- BIAF 1
- APLM 0
- Target Price
- BIAF N/A
- APLM N/A
- AVG Volume (30 Days)
- BIAF 468.1K
- APLM 36.1K
- Earning Date
- BIAF 08-14-2025
- APLM 09-19-2025
- Dividend Yield
- BIAF N/A
- APLM N/A
- EPS Growth
- BIAF N/A
- APLM N/A
- EPS
- BIAF N/A
- APLM N/A
- Revenue
- BIAF $7,681,059.00
- APLM $198,000.00
- Revenue This Year
- BIAF N/A
- APLM $415.15
- Revenue Next Year
- BIAF $20.00
- APLM N/A
- P/E Ratio
- BIAF N/A
- APLM N/A
- Revenue Growth
- BIAF 4.99
- APLM N/A
- 52 Week Low
- BIAF $0.16
- APLM $3.66
- 52 Week High
- BIAF $2.26
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- BIAF 39.54
- APLM 46.73
- Support Level
- BIAF $0.24
- APLM $3.66
- Resistance Level
- BIAF $0.26
- APLM $6.37
- Average True Range (ATR)
- BIAF 0.02
- APLM 0.56
- MACD
- BIAF 0.00
- APLM -0.06
- Stochastic Oscillator
- BIAF 17.02
- APLM 55.37
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.